IP Library Granted Patent US 8,728,492
Granted Patent B2
US 8,728,492 · App. 12/863,040 · Granted May 20, 2014

Malaria vaccine compositions and constituents which elicit cell mediated immunity

Inventors: Avigdor Shafferman (Nexx Ziona, IL); Anat Zvi (Gedera, IL); John Fulkerson (Silver Spring, MD); Jerald C. Sadoff (Washington, DC)
Assignee: Aeras Global TB Vaccine Foundation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,728,492
App. No.
12/863,040
Granted
May 20, 2014
Kind
B2
Abstract

Malaria vaccines based on polyepitope constructs that elicit cell-mediated immunity against a broad spectrum of malaria parasites and which cover the majority of HLA alleles are provided. Epitopes in the polyepitope constructs are from regions of the Plasmodium falciparum circumsporozoite protein (CSP) known to contain CD4 and CD8 T cell epitopes, and include both epitopes from highly variable and highly conserved regions of CSP.

Claims (6)

1. A recombinant antigenic polypeptide comprising one or more copies of the amino acid sequence MMRKLAILSVSSFLFVEALFQEYQCYGSSKMEKCSSVFNVVNSSI GLIMVLSFLFLN (SEQ ID NO: 38).

2. The recombinant antigenic polypeptide of claim 1 , wherein the polypeptide comprises multiple copies of the amino acid sequence which are i) located directly adjacent to one another; or ii) separated from each other by spacer peptides that permit authentic carboxy terminal proteolytic cleavage within said recombinant antigenic polypeptide.

3. A nucleic acid encoding an antigenic polypeptide, wherein the polypeptide comprises one or more copies of the amino acid sequence MMRKLAILSVSSFLFVEALFQEYQCYGSSKMEKCSSVFNVVNSSIGLIMVLSFLFLN (SEQ ID NO: 38).

4. The nucleic acid of claim 3 , wherein the polypeptide comprises multiple copies of the amino acid sequence which are i) located directly adjacent to one another; or ii) separated from each other by spacer peptides that permit authentic carboxy terminal proteolytic cleavage within said recombinant antigenic polypeptide.

5. A method of immunizing an individual against malaria, comprising the step of administering to said individual a recombinant antigenic polypeptide comprising one or more copies of the amino acid sequence MMRKLAILSVSSFLFVEALFQEYQCYGSSKMEKCSS VFNVVNSSIGLIMVLSFLFLN (SEQ ID NO: 38).

6. The method of claim 5 , wherein the polypeptide comprises multiple copies of the amino acid sequence which are i) located directly adjacent to one another; or ii) separated from each other by spacer peptides that permit authentic carboxy terminal proteolytic cleavage within said recombinant antigenic polypeptide.

Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 18, 2018
From: AERAS
To: INTERNATIONAL AIDS VACCINE INITIATIVE, INC.
Reel/Frame 047219/0870 →
CHANGE OF NAME Recorded Dec 27, 2016
From: AERAS GLOBAL TB VACCINE FOUNDATION
To: AERAS
Reel/Frame 041303/0681 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 27, 2011
From: SHAFFERMAN, AVIGDOR; ZVI, ANAT; FULKERSON, JOHN; SADOFF, JERALD C.
To: AERAS GLOBAL TB VACCINE FOUNDATION
Reel/Frame 026366/0563 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 5, 2011
From: SHAFFERMAN, AVIGDOR; ZVI, ANAT; FULKERSON, JOHN; SADOFF, JERALD C.
To: AERAS GLOBAL TB VACCINE FOUNDATION
Reel/Frame 026232/0171 →
Continuity (2)
Provisional Application 61021996 · Jan 18, 2008
Related Publication 20110206714A1 · Aug 25, 2011